Big pharmaceutical companies are facing a barrage of legislative proposals that could have a dramatic impact on the industry’s future earnings power and open doors to one of its biggest threats: generic drug manufacturers.

A proposal set to be unveiled on Wednesday by Hillary Clinton, the Democratic presidential hopeful, and a bipartisan group of lawmakers would allow generic drugmakers to manufacture cheaper versions of biotechnology drugs produced by companies such as Amgen and Genentech.